KR920002627A - α-케토 아미드 유도체 - Google Patents

α-케토 아미드 유도체 Download PDF

Info

Publication number
KR920002627A
KR920002627A KR1019910012754A KR910012754A KR920002627A KR 920002627 A KR920002627 A KR 920002627A KR 1019910012754 A KR1019910012754 A KR 1019910012754A KR 910012754 A KR910012754 A KR 910012754A KR 920002627 A KR920002627 A KR 920002627A
Authority
KR
South Korea
Prior art keywords
group
protected
residue
amino acid
compound
Prior art date
Application number
KR1019910012754A
Other languages
English (en)
Inventor
데쓰야 소메노
후미카 야마다
히데오 스기무라
야스히코 무라오카
마코토 쓰다
도미오 다케우치
다카아키 아오야기
Original Assignee
다케다 가주히코
닛뽄가야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 가주히코, 닛뽄가야쿠 가부시키가이샤 filed Critical 다케다 가주히코
Publication of KR920002627A publication Critical patent/KR920002627A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

내용 없음

Description

α-케토 아미드 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (26)

  1. 하기 일반식(1)의 신규한 α-케토 아미드 유도체 또는 이의 염:
  3. 상기식에서, X는 작용성 그룹이 보호될 수 있는 펩티드잔기 또는 아미노산 잔기이거나, 수소원자 또는 아미노-보호그룹이며; Y는 작용성 그룹이 보호될 수 있는 펩티드잔기 또는 아미노산 잔기이고; E는 알킬렌(CnH2n-1)상의 치환체를 나타내며, 할로겐, 저급알콕시 또는 수소이고; A는 카보닐그룹이거나, 일-또는 이-치환된 메틸렌이고, 이때 치환체 하이드록시, 저급알콕시, 페닐이미노 또는 벤질이미노이고; n은 2내지 6중의 한 정수이다.
  4. 제1항에 있어서, X가 저급알킬(C1-6)카보닐, 아미노그룹이 보호될 수 있는 α-아미노산 잔기, 또는 아미노 그룹이 보호될 수 있는 α-아미노산을 함유하는 디펩티드잔기이며; E는 수소이고, n은 3인 화합물.
  5. 제2항에 있어서, Y가 작용성 그룹이 보호될 수 있는 아미노산잔기 또는 작용성 그룹이 보호될 수 있는 디펩티드 잔기인 화합물.
  6. 제2항에 있어서, X가 측쇄 알킬(C3-6)카보닐, 아미노그룹이 보호되는 α-아미노알킬((C1-5)카보닐, N-보호된-2-피롤리디닐카보닐, 또는 아미노산그룹이 보호될 수 있는 α-아미노산(C2-10)을 함유하는 디펩티드잔기인 화합물.
  7. 제2항에 있어서, Y가 α-카복시그룹이 보호될 수 있는 α-카복시알킬(C1-6)아미노그룹인 화합물.
  8. 제4항에 있어서, X가 측쇄 알킬(C3-6)카보닐, Z-Phe-, Z-Pro-또는 Z-Val-Val이며; Y는 카복실그룹이 보호 또는 비보호될 수 있는 류신 또는 글리신잔기이거나, 카복실그룹이 보호되는 -Leu-Val인 화합물.
  9. 제4항에 있어서, A가 카보닐그룹인 화합물.
  10. 제5항에 있어서, Y가 카복실그룹이 비보되는 류신 또는 글리신잔기이거나, 카복실그룹이 보호되는 류신 또는 글리신 잔기이거나, 카복실그룹이 에스테르형 보호그룹 또는 아미드형 보호그룹에 의해 보호되는 -Leu-Val인 화합물.
  11. 제5항에 있어서, 카복실그룹이 알킬(C1-6)그룹 또는 알킬(C1-6)아미드그룹에 의해 보호되는 화합물.
  12. 제6항에 있어서, X가 (CH3)3CCH2CO- 또는 Z-Phe-인 화합물.
  13. 제10항에 있어서, Y가 -Leu-OH, -Leu-NH(t-Bu), -Leu-O(t-Bu), -Leu-OBzl, Gly-OH 또는 -Gly-O(t-Bu)인 화합물.
  15. 중에서 선택된 화합물 또는 이의 염.
  16. 내용없음
  17. 하기 일반식의 α-하이드록시아세트산 유도체:
  19. 상기식에서, X'는 작용성 그룹이 보호될 수 있는 펩티드잔기 또는 아미노산 잔기이거나, 아미노-보호그룹이며; Y'는 작용성 그룹이 보호되는 펩티드잔기 또는 아미노산 잔기이고; n은 2내지 6중의 한 정수이다.
  20. 하기 일반식(1")의 α-하이드록시아세트산 유도체를 산화시키고; 필요한 경우, 보호그룹을 제거함으로써 하기 일반식(1')의 신규한 α-케토 아미드유도체 또는 이의 염을 제조하는 방법;
  22. 상기식에서, X는 작용성 그룹이 보호될 수 있는 펩티드잔기 또느 아미노산 잔기이거나, 수소원자 또는 아미노-보호그룹이며; X'는 작용성 그룹이 보호되는 펩티드잔기 또는 아미노산 잔기이거나, 아미노-보호그룹이고; Y는 작용성 그룹이 보호될 수 있는 펩티드잔기 또는 아미노산 잔기이며; Y'는 작용성 그룹이 보호되는 펩티드잔기 또는 아미노산 잔기이고; E는 알킬렌(CnH2n-1)상의 치환체를 나타내며, 할로겐, 저급알콕시 또는 수소이며; A'는 카보닐그룹이거나, 일-또는 이-치환된 메틸렌이고, 이때 치환체는 저급알콕시, 페닐이미노 또는 벤질이미노이고; n은 2내지 6중의 한 정수이다.
  23. 제14항에 있어서, E가 수소이며, n은 정수 3인 신규한 α-케토 아미드유도체 또는 이의 염을 제조하는 방법.
  24. 제15항에 있어서, 하이드록실그룹을 산화제의 존재하에 산화시킴으로써 반응을 수행하여 신규한 α-케토아미드 유도체 또는 이의 염을 제조하는 방법.
  25. 제16항에 있어서, 불활성 유기 용매중에서 -10℃내지 용매의 비점에서 반응을 수행하여 신규한 α-케토아미드 유도체 또는 이의 염을 제조하는 방법.
  26. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910012754A 1990-03-01 1991-07-25 α-케토 아미드 유도체 KR920002627A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP91-57753 1990-03-01
JP90-197753 1990-07-27
JP19775390 1990-07-27
JP3057753A JPH04211648A (ja) 1990-07-27 1991-03-01 ケト酸アミド誘導体

Publications (1)

Publication Number Publication Date
KR920002627A true KR920002627A (ko) 1992-02-28

Family

ID=26398823

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012754A KR920002627A (ko) 1990-03-01 1991-07-25 α-케토 아미드 유도체

Country Status (6)

Country Link
US (1) US5221752A (ko)
EP (1) EP0468339B1 (ko)
JP (1) JPH04211648A (ko)
KR (1) KR920002627A (ko)
DE (1) DE69125537T2 (ko)
ES (1) ES2102989T3 (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
DE69428703T2 (de) * 1993-07-23 2002-05-29 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokio/Tokyo Pyrrolidin derivate
WO1995003278A1 (fr) * 1993-07-26 1995-02-02 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Derive de pyrrolidine ou sel de celui-ci pharmaceutiquement acceptable
WO1996016079A2 (en) * 1994-11-24 1996-05-30 Takeda Chemical Industries, Ltd Alpha-ketoamide derivatives as cathepsin l inhibitor
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
TW498068B (en) 1996-09-06 2002-08-11 Nippon Kayaku Kk Novel acetamide derivatives and protease inhibitors
US5786378A (en) * 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US6218424B1 (en) 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5801187A (en) 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
CA2334204A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Heterocyclic ester and amide hair growth compositions and uses
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
EP2289887A3 (en) 2000-06-30 2011-07-06 Seikagaku Corporation Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
ATE342261T1 (de) * 2001-09-21 2006-11-15 Novartis Pharma Gmbh Pyranderivate als inhibitoren von ace und nep
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626545A (en) * 1984-08-27 1986-12-02 Merck & Co., Inc. Amino acid derivatives as enzyme inhibitors
US4880827A (en) * 1986-03-18 1989-11-14 Sumitomo Pharmaceuticals Company, Ltd. Pyrrolidine derivatives having inhibitory action for proline specific endopepidase

Also Published As

Publication number Publication date
EP0468339A3 (en) 1993-02-17
DE69125537T2 (de) 1997-07-17
DE69125537D1 (de) 1997-05-15
EP0468339A2 (en) 1992-01-29
JPH04211648A (ja) 1992-08-03
EP0468339B1 (en) 1997-04-09
ES2102989T3 (es) 1997-08-16
US5221752A (en) 1993-06-22

Similar Documents

Publication Publication Date Title
KR920002627A (ko) α-케토 아미드 유도체
KR960703858A (ko) 물질 p 길항제로서의 퍼히드로이소인돌 유도체(perhydroisoindole derivatives as substance p antagonists)
RU96115394A (ru) Производные камптотецина
RU93005332A (ru) Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения
KR920700208A (ko) 탁솔유도체 화합물과 그의 제조방법
KR910011891A (ko) 펩티드 화합물, 이의 제조방법 및 이를 함유하는 약학적 조성물
KR927003520A (ko) 펩티딜(peptidyl) 유도체
DE69132363D1 (de) Chelat-zubereitung, die alpha-diamin-verbindungen enthalten
KR930004287A (ko) 2-피페라지논 화합물, 그의 제조 방법 및 용도
KR880003974A (ko) 디아민의 선택적 아미딘화 방법
IE801342L (en) Peptides
ES8800919A1 (es) Procedimiento para preparar nuevos derivados de acidos tiazolidin-4(s)-carboxilicos
ES8200645A1 (es) Un procedimiento para la preparacion de un muramildipeptido.
KR870004019A (ko) 퀴놀린 유도체의 제조방법
KR920014828A (ko) 신규한 종양 성장-억제 소마토스타틴 동족체, 이 동족체를 함유하는 제약 조성물 및 그 제조방법
KR970707076A (ko) 금속단백질 분해효소 억제제(Metalloproteinase Inhibitors)
KR900009692A (ko) 레트로바이러스 프로테아제 억제제
KR950000695A (ko) 헤테로환식 고리를 함유하는 우레아 유도체
WO2010146119A1 (en) Preparation process of an antivirally heterocyclic azahexane derivative
KR860003272A (ko) 펩타이드-치환된-헤테로사이클릭 화합물의 제조방법
KR930021621A (ko) 프로페노일-이미다졸 유도체
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
EP2139910B1 (fr) Procede de synthese de peptides sans solvant
DE69503213D1 (de) Baccatin-Derivate und Verfahren zu deren Herstellung
KR840002807A (ko) 4-시아노-2-아제티디논 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee